SCHEMBL14828635

SCHEMBL14828635

CC(C)c1cc(F)c2[nH]c(=O)ccc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.54
CA9 Q16790 5/20 0.54
EIF4A3 P38919 4/20 0.40
DAO P14920 1/20 0.38
DDO Q99489 1/20 0.38
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
MAPK1 P28482 1/20 0.32
F11 P03951 1/20 0.32
CA1 P00915 1/20 0.32
CA3 P07451 1/20 0.32
CA4 P22748 1/20 0.32
CA6 P23280 1/20 0.32
CA5A P35218 1/20 0.32
CA7 P43166 1/20 0.32
CA13 Q8N1Q1 1/20 0.32
CA14 Q9ULX7 1/20 0.32
CA5B Q9Y2D0 1/20 0.32
AKR1C3 P42330 1/20 0.31
AKR1C2 P52895 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20125007 0.80 CA12 (0.50) CA12CA9EIF4A3DAOMAPT
SCHEMBL19737508 0.80 CA12 (0.50) CA12CA9EIF4A3MAPTTHRB
SCHEMBL19737581 0.79 HDAC4 (0.42) CA12CA9MAPTTHRB
SCHEMBL2165918 0.78 CA12 (0.60) CA12CA9DAODDOMAPK1
SCHEMBL12559602 0.77 CA12 (0.55) CA12CA9EIF4A3DAODDO
SCHEMBL21729420 0.76 MCL1 (0.44) CA12CA9EIF4A3MAPTTHRB
SCHEMBL19737649 0.76 CA12 (0.36) CA12CA9EIF4A3MAPTTHRB
SCHEMBL19737419 0.76 HCAR1 (0.38) CA12CA9PDE2A
SCHEMBL19737431 0.75 ADORA3 (0.43) CA12CA9MAPTMAPK1CA1
SCHEMBL18876058 0.74 SLC6A2 (0.40) EIF4A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3318557-A2 QUINOLONE COMPOUND Otsuka Pharmaceutical Co., Ltd. (JP) 2018-05-09 EP disclosed
US-20130085138-A1 Selective NR2B Antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085138-A1 Selective NR2B Antagonists GRIN2B, GRIN2A, GRIN3A CA12 3374/4885CA9 4684/4885EIF4A3 2945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.